Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
A phase i/ii, open-label, single-arm, two-part trial to evaluate safety, tolerability, pharmacokinetics, and anti-tumor activity of glofitamab in combination with chemoimmunotherapy in pediatric and young adult participants with relapsed/refractory mature b-cell non-hodgkin lymphoma
Protocol ID
CO43810
Disease (Sub Disease)
Non-hodgkin lymphoma
Diagnosis Stage
Relapsed/refractory
Sponsor
Hoffmann-La Roche
Trial Status
Preparing to Open
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
6 Months to 30 Years
International registry ID's
NCT05533775
Back to Registry
Study Title A phase i/ii open-label single-arm two-part trial to evaluate safety tolerability pharmacokinetics and anti-tumor activity of glofitamab in combination with chemoimmunotherapy in pediatric and young adult participants with relapsed/refractory mature b-cell non-hodgkin lymphoma
Protocol ID CO43810
Disease (Sub Disease) Non-hodgkin lymphoma
Diagnosis Stage Relapsed/refractory
Sponsor Hoffmann-La Roche
Links https://clinicaltrials.gov/ct2/show/NCT05533775
Trial Status Preparing to Open
Study Type Treatment
Phase Phase 1/2
Age Eligibility 6 Months to 30 Years
International registry ID's NCT05533775